The whole point of the game-changing cancer immunotherapies is to get armadas of T cells sailing into battle against tumors. But for some patients there’s a fundamental problem: Their T cells aren’t armed — or, in bio-speak, “activated,” a big reason why many patients aren’t helped by much-hyped new therapies.

If a new technique reported on Monday works in people as well as it does in lab mice, however, physicians will be able to tell almost immediately if a patient’s immune system is armed and, if it’s not, quickly switch therapies, increase dosages, or just spare patients often-serious side effects.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy